CareDx appoints Dr. Grace Colón to its Board of Directors

– USA, CA –  CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Grace Colón, Ph.D. has joined CareDx’s Board of Directors.

“Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare, and industrial biotechnology and has committed the last 6 years to develop transformative therapies for cardiac conditions. Her contributions will be invaluable as we further develop the CareDx product pipeline,” said Peter Maag, CareDx CEO.

About Dr Grace Colón

Dr. Colón has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company developing therapeutics for cardiovascular conditions since 2013. In addition to her role at InCarda, she is also Executive Chairman (formerly CEO) of ProterixBio, and is on the board of Cocoon Biotech. Previously, she served on the boards of Paradigm Diagnostics and PerceptiMed. She was formerly a partner at New Science Ventures and held various leadership roles at Intrexon Corporation, Gilead Sciences, and Affymetrix. Earlier in her career, she was an engagement manager with McKinsey & Co.

“I am excited to work with the CareDx management team and board at a time of tremendous growth and innovation and delighted to have the opportunity to contribute to the mission of improving transplant patient outcomes,” said Grace Colón.

Dr. Colón received her B.S. in chemical engineering from the University of Pennsylvania and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along with the pre- and post-transplant testing continuum and is the leading provider of genomics-based information for transplant patients.

For more information, visit www.CareDx.com.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.